Literature DB >> 20638779

miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2.

Yihui Ma1, Shuangni Yu, Wugan Zhao, Zhaohui Lu, Jie Chen.   

Abstract

MicroRNAs are short regulatory RNAs. A growing body of data implicates altered miRNA participate in the development of cancers and miR-27a is abnormally upregulated in several types of cancers identified as an oncogene. Although overexpressed in pancreatic adenocarcinoma, the oncogenic role of miR-27a has not yet been reported. In this study, we showed that inhibition of miR-27a suppressed the growth, colony formation and migration of pancreatic cancer cells. By using a reporter-screening assay, we discovered that the 3'UTR of Sprouty2 (Spry2) carried a putative miR-27a binding site. Furthermore, the Spry2 protein, which has a low expression level in pancreatic adenocarcinoma, was upregulated by transfection with a miR-27a inhibitor. The data reported here are the first to indicate that miR-27a plays an oncogenic role by targeting Spry2 and modulating the malignant, biological behavior of pancreatic cancer cells. This suggests the potential for miR-27a to be used as a target in the diagnosis and treatment of pancreatic adenocarcinoma.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638779     DOI: 10.1016/j.canlet.2010.06.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  84 in total

1.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 2.  MicroRNAs in pancreatic malignancy: progress and promises.

Authors:  Sanjeev K Srivastava; Sumit Arora; Seema Singh; Arun Bhardwaj; Courey Averett; Ajay P Singh
Journal:  Cancer Lett       Date:  2014-02-20       Impact factor: 8.679

3.  miR-27a promotes cell proliferation and metastasis in renal cell carcinoma.

Authors:  Hongjun Peng; Xianjun Wang; Pei Zhang; Tao Sun; Xianguo Ren; Zhengkun Xia
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis.

Authors:  Shanliang Zhong; Zhiyuan Chen; Jinjin Xu; Wenjing Li; Jianhua Zhao
Journal:  Mol Biol Rep       Date:  2012-12-25       Impact factor: 2.316

Review 5.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

6.  Increased Expression of MiR-27a and MiR-24-2 in Esophageal Squamous Cell Carcinoma.

Authors:  Mohaddese Maghsudlu; Ehsan Farashahi Yazd; Taghi Amiriani
Journal:  J Gastrointest Cancer       Date:  2020-03

7.  * Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia.

Authors:  Anthony Monteforte; Brian Lam; Michael B Sherman; Kayla Henderson; Andrew D Sligar; Adrianne Spencer; Brian Tang; Andrew K Dunn; Aaron B Baker
Journal:  Tissue Eng Part A       Date:  2017-11       Impact factor: 3.845

Review 8.  Developments in miRNA gene signaling pathways in pancreatic cancer.

Authors:  Christina Vorvis; Marina Koutsioumpa; Dimitrios Iliopoulos
Journal:  Future Oncol       Date:  2016-03-17       Impact factor: 3.404

9.  Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.

Authors:  Christina Vorvis; Maria Hatziapostolou; Swapna Mahurkar-Joshi; Marina Koutsioumpa; Jennifer Williams; Timothy R Donahue; George A Poultsides; Guido Eibl; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-05       Impact factor: 4.052

10.  microRNA signature for human pancreatic cancer invasion and metastasis.

Authors:  He Cheng; Si Shi; Xiaochen Cai; Jiang Long; Jin Xu; Chen Liu; Xianjun Yu
Journal:  Exp Ther Med       Date:  2012-05-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.